RIPK1-IN-22
RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pKi of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC50 of 7.2[1].
Product Specifications
UNSPSC
12352005
Target
RIP kinase
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ripk1-in-22.html
Solubility
10 mM in DMSO
Smiles
CN(C1=CN=C(OC)C=C1CC[C@@H]2C(NC3=NC=C(CC4=CC=CC=C4)S3)=O)C2=O
Molecular Formula
C22H22N4O3S
Molecular Weight
422.50
References & Citations
[1]Petró JL, et al., Design, synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors. Bioorg Med Chem Lett. 2024 Mar 1;100:129643.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSH032013-01 10 µg
Recombinant Human CSF1R/CD115 Protein (aa 20-517, His Tag)
Sign In for Pricing
View Details PKSH032013-02 50 µg
Recombinant Human CSF1R/CD115 Protein (aa 20-517, His Tag)
Sign In for Pricing
View Details 